MR Imaging of Ductal Carcinoma In Situ

Magnetic Resonance Imaging Clinics of North America

Volumn 18, Issue 2, 2010, Pages 225-240

  Newstead, Gillian M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

DCIS; Ductal carcinoma in situ; Mammography; MR imaging

Indexed keywords

TAMOXIFEN;

BREAST BIOPSY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PROGNOSIS; RELIABILITY; REVIEW;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MICE; SENSITIVITY AND SPECIFICITY;

EID: 77953001884     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2010.02.004     Document Type: Review

References (71)

1. Leonard G.D., Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004, 96:906-920.
2. Page D.L., DuPont W.D., Rogers L.W., et al. Intraductal carcinoma of the breast. Follow-up after biopsy only. Cancer 1982, 49:751-758.
3. Ernster V.L., Ballard-Barbash R., Barlow W.E., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
4. MacCarty W.C. The histogenesis of cancer (carcinoma) of the breast and its clinical significance. Surg Gynecol Obstet 1913, 17:441-459.
5. Broders A.C. Carcinoma in situ contrasted with benign penetrating epithelium. JAMA 1932, 99:1670-1674.
6. Dershaw D.D., Abramson A., Kinne D.W. Ductal carcinoma in situ: mammographic findings and clinical implications. Radiology 1989, 170:411-415.
7. Homer M.J., Safaii H., Smith J.J., et al. The relationship of mammographic microcalcification to histologic malignancy: radiologic-pathologic correlation. AJR Am J Roentgenol 1989, 153:1187-1189.
8. Bassett L.W. Mammographic analysis of calcifications. Radiol Clin North Am 1992, 30:93-105.
9. Stomper P.C., Connolly J.L., Meyer J.E., et al. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology 1989, 172(1):235-241.
10. Lafontan B., Daures J.P., Salicru B., et al. Isolated clustered microcalcifications: diagnostic value of mammography-series of 400 cases with surgical verification. Radiology 1994, 190:479-483.
11. Ikeda D.M., Andersson I. Ductal carcinoma in situ: atypical mammographic appearances. Radiology 1989, 172:661-666.
12. Koerner F.C. A brief historical perspective on the pathology of the breast: from Cheatle to Azzopardi and beyond. Semin Diagn Pathol 2004, 21(1):3-9.
13. Finney J.M. Joseph Colt Bloodgood 1867-1935. Ann Surg 1937, 105(91):150-151.
14. Mitnick J.S., Roses D.F., Harris M.N., et al. Circumscribed intraductal carcinoma of the breast. Radiology 1989, 170:423-425.
15. Farshid G., Downey P., Gill P.G. Atypical presentations of screen-detected DCIS: implications for pre-operative assessment and surgical intervention. Breast 2007, 16:161-171.
16. The National Cancer Institute (NCI). Overview of the SEER Cancer Statistics Review 1975-2005. Available at: Accessed February 5, 2010. http://seer.cancer.gov/csr/1975_2005/results_single/sect_01_intro.28pgs.pdf.
17. American Cancer Society. Cancer facts and figures 2009. Atlanta (GA): American Cancer Society; 2009. p. 3-11.
18. Davis R., Stacey A.J. The detection and significance of calcifications in the breast: a radiologic and pathologic study. Br J Radiol 1976, 49:12-26.
19. Dongen J., Harris J.R., Peterse J.L., et al. In situ breast cancer: the EORTC consensus meeting. Lancet 1989, 8653:25-27.
20. Dongen J.A., Holland R., Peterse J.L., et al. Ductal carcinoma in-situ of the breast; second EORTC consensus meeting [review]. Eur J Cancer 1992, 28(2):626-629.
21. Holland R., Hendriks J.H., Verbeek A.L., et al. Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ. Lancet 1990, 335:519-522.
22. Stomper P.C., Connolly J.L. Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. Am J Roentgenol 1992, 159:483-485.
23. Tabar L. Ductal carcinoma in situ. Mod Pathol 1990, 3(4):440.
24. James J.J., Evans A.J., Pinder S.E., et al. Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?. Clin Radiol 2003, 58(1):54-62.
25. Peacock C., Given-Wilson R.M., Duffy S.W. Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator?. Clin Radiol 2004, 59(2):165-170. [discussion: 163-4].
26. Tabar L., Chen H.H., Yen A.M., et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 2004, 101(8):1745-1759.
27. Thurfjell E., Thurfjell M.G., Lindgren A. Mammographic finding as predictor of survival in 1-9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 2001, 67(2):177-180.
28. Zunzunegui R.G., Chung M.A., Oruwari A., et al. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?. Arch Surg 2003, 138(5):537-540.
29. Tabar L., Tot T., Dean P.B. Breast cancer: early detection with mammography 2007, Georg Thieme Verlag, Stuttgart (Germany), 129-72.
30. Hieken T.J., Farolan M., D'Alessandro S., et al. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. Surgery 2001, 130:593-600.
31. Ringberg A., Anagnostaki L., Anderson H., South Sweden Breast Cancer Group, et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001, 37:1514-1522.
32. Bobrow G.L., Happerfield L.C., Gregory W.M., et al. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994, 11:199-207.
33. Recht A., Rutgers E.J., Fentiman I.S., et al. The fourth EORTC DCIS consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23-24 January 1998)-conference report. Eur J Cancer 1998, 34:1664-1669.
34. Holland H., Peterse J.L., Millis R.R., et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11:167-180.
35. Silverstein M.J., Poller D.N., Waismann J.R., et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995, 345:1154-1157.
36. Silverstein M.J., Lagios M.D., Craig P.H., et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77:2267-2274.
37. Bijker N., Peterse J.L., Duchateau L., et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001, 19:2263-2271.
38. Kuhl C.K., Mielcareck P., Klaschik S., et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology 1999, 211(1):101-110.
39. Boetes C., Strijk S.P., Holland R., et al. False negative MR imaging of malignant breast tumors. Eur Radiol 1997, 7(8):1231-1234.
40. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427-437.
41. Warner E., Plewes D.H., Hill K.A., et al. Surveillance of BRCA 1 and BRCA 2 mutation carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast examination. JAMA 2005, 292:1317-1325.
42. Leach M.O., Boggis C.R., Dixon A.K., et al. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
43. Morris E., Liberman L. Ductal carcinoma in situ. Breast MRI: diagnosis and intervention 2004, 164-172. Springer, Philadelphia. E.A. Morris, L. Liberman (Eds.).
44. Kuhl C.K., Schrading S., Bieling H., et al. MRI for diagnosis of pure ductal carcinoma in-situ; a prospective observational study. Lancet 2007, 370:485-492.
45. Kaiser W.A., Zeitler E. MR imaging of the breast: fast imaging sequences with and without GD-TPA. Radiology 1989, 170:681-686.
46. Orel S.G. High-resolution MR imaging for the detection, diagnosis and staging of breast cancer. Radiographics 1998, 18:903-912.
47. Heywang-Kobrunner S.H., Viehweg P., Heinig A., et al. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997, 24:94-108.
48. ACR. American College of Radiology (ACR) breast imaging reporting and data system atlas (BI-RADS). Reston (VA): ACR; 2003.
49. Jansen S.A., Fan X., Karczmar G.S., et al. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and non-mass-like enhancement?. Med Phys 2008, 35(7):3102-3109.
50. Neubauer H., Li M., Kuehne-Heid R., et al. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 2003, 76:3-12.
51. Van Goethem M., Schelfout K., Kersschot E., et al. Comparison of MRI features of different grades of DCIS and invasive carcinoma of the breast. JBR-BTR 2005, 88:225-232.
52. Harms S.E. The use of breast magnetic resonance imaging in ductal carcinoma in situ. Breast J 2005, 11:379-381.
53. Boetes C., Barentsz J.O., Mus R.D., et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994, 193:777-781.
54. Sardanelli F., Rescinito G., Giordano G.D., et al. MR dynamic enhancement of breast lesions: high temporal resolution during the first-minute versus eight-minute study. J Comput Assist Tomogr 2000, 24:724-731.
55. Jansen S.A., Newstead G.M., Abe H., et al. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology 2007, 245:684-691.
56. Viehweg P., Lampe D., Buchmann J., et al. In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging. MAGMA 2000, 11(3):129-137.
57. Guidi A.J., Schnitt S.J., Fischer L., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997, 80:1945-1953.
58. Heffelfinger S.C., Miller M.A., Yassin R., et al. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 1999, 5(10):2867-2876.
59. Heffelfinger S.C., Yassin R., Miller M.A., et al. Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. Clin Cancer Res 1996, 2(11):1873-1878.
60. Esserman L., Hylton N., George T., et al. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 1999, 5(1):13-21.
61. Menell J.H., Morris E.A., Dershaw D.D., et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 2005, 11:382-390.
62. Morakkabati-Spitz N., Leutner C., Schild H., et al. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005, 15:2010-2017.
63. Rosen E.L., Smith-Foley S.A., DeMartini W.B., et al. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J 2007, 13:545-550.
64. Tozaki M., Igarashi T., Fukuda K. Breast MRI using the VIBE sequence: clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement. AJR Am J Roentgenol 2006, 187(2):313-321.
65. Jansen S.A., Shimauchi A., Zak L., et al. Kinetic curves of malignant lesions are not consistent across MR systems: the need for improved standardization of breast DCEMRI acquisitions. AJR Am J Roentgenol 2009, 193(3):832.
66. Williams T.C., DeMartini W.B., Partridge S.C., et al. Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions. Radiology 2007, 244:94-103.
67. Bartella L., Thakur S.B., Morris E.A., et al. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007, 245:80-87.
68. Bleicher R.J., Ciocca R.M., Egleston B.L., et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009, 209:180-187. © 2009.
69. Veltman J., Stoutjesdijk M., Mann R., et al. Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. Eur Radiol 2008, 18(6):1123-1133.
70. Oshida K., Nagashima T., Ueda T., et al. Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. Eur Radiol 2005, 15(7):1353-1360.
71. Jansen S.A., Paunesku T., Fan X., et al. X-ray fluorescence microscopy and dynamic contrast enhanced MR imaging of gadolinium uptake within the mammary ducts. Radiology 2009, 253(2):399-406.